Titre : Doxapram

Doxapram : Questions médicales fréquentes

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment le doxapram est-il utilisé dans le diagnostic ?

Il est utilisé pour évaluer la fonction respiratoire en stimulant la respiration.
Doxapram Fonction respiratoire
#2

Quels tests peuvent nécessiter du doxapram ?

Des tests de fonction pulmonaire peuvent nécessiter l'administration de doxapram.
Tests de fonction pulmonaire Doxapram
#3

Le doxapram est-il utilisé en urgence ?

Oui, il peut être administré en cas d'insuffisance respiratoire aiguë.
Insuffisance respiratoire Doxapram
#4

Quels signes cliniques indiquent l'utilisation du doxapram ?

Une hypoventilation ou une dépression respiratoire peuvent justifier son utilisation.
Hypoventilation Doxapram
#5

Le doxapram est-il utilisé pour le diagnostic de l'apnée ?

Il peut être utilisé pour évaluer la réponse respiratoire en cas d'apnée.
Apnée Doxapram

Symptômes 5

#1

Quels symptômes le doxapram traite-t-il ?

Il traite les symptômes d'insuffisance respiratoire et de dépression respiratoire.
Insuffisance respiratoire Doxapram
#2

Le doxapram peut-il provoquer des effets secondaires ?

Oui, des effets secondaires comme l'hypertension ou des palpitations peuvent survenir.
Effets secondaires Doxapram
#3

Quels symptômes indiquent une surdose de doxapram ?

Des symptômes comme l'anxiété, des tremblements ou des convulsions peuvent apparaître.
Surdose Doxapram
#4

Le doxapram soulage-t-il la dyspnée ?

Oui, il peut soulager la dyspnée en stimulant la respiration.
Dyspnée Doxapram
#5

Quels signes d'alerte nécessitent une attention médicale ?

Des signes comme des douleurs thoraciques ou des difficultés respiratoires doivent alerter.
Douleurs thoraciques Doxapram

Prévention 5

#1

Comment prévenir les complications respiratoires ?

La prévention inclut la vaccination et la gestion des maladies respiratoires chroniques.
Complications respiratoires Prévention
#2

Le doxapram peut-il prévenir l'apnée du sommeil ?

Non, il ne prévient pas l'apnée du sommeil, mais peut aider en cas de crise.
Apnée du sommeil Doxapram
#3

Quelles mesures préventives sont recommandées ?

Éviter le tabagisme et maintenir un poids santé sont des mesures préventives.
Tabagisme Prévention
#4

Le doxapram est-il préventif ou curatif ?

Le doxapram est principalement un traitement curatif, pas préventif.
Traitement Doxapram
#5

Comment gérer les risques respiratoires ?

La gestion des risques inclut le suivi médical régulier et l'éducation des patients.
Risques respiratoires Gestion

Traitements 5

#1

Comment le doxapram est-il administré ?

Il est généralement administré par voie intraveineuse ou intramusculaire.
Administration intraveineuse Doxapram
#2

Le doxapram est-il utilisé en soins intensifs ?

Oui, il est souvent utilisé en soins intensifs pour les patients en détresse respiratoire.
Soins intensifs Doxapram
#3

Combien de temps dure l'effet du doxapram ?

L'effet du doxapram dure généralement de 30 minutes à 2 heures.
Durée d'action Doxapram
#4

Le doxapram peut-il être utilisé chez les enfants ?

Oui, il peut être utilisé chez les enfants sous surveillance médicale.
Enfants Doxapram
#5

Quelles sont les alternatives au doxapram ?

Des médicaments comme la théophylline ou les bronchodilatateurs peuvent être utilisés.
Théophylline Bronchodilatateurs

Complications 5

#1

Quelles complications peuvent survenir avec le doxapram ?

Des complications comme l'hypertension ou des arythmies cardiaques peuvent survenir.
Hypertension Doxapram
#2

Le doxapram peut-il causer des problèmes cardiaques ?

Oui, il peut provoquer des arythmies, surtout en cas de surdosage.
Problèmes cardiaques Doxapram
#3

Comment gérer les effets indésirables du doxapram ?

La gestion inclut l'arrêt du médicament et le traitement des symptômes associés.
Effets indésirables Doxapram
#4

Le doxapram peut-il interagir avec d'autres médicaments ?

Oui, il peut interagir avec des médicaments comme les antidépresseurs ou les anesthésiques.
Interactions médicamenteuses Doxapram
#5

Quels signes indiquent une complication grave ?

Des signes comme des douleurs thoraciques ou des troubles de la conscience doivent alerter.
Complications graves Doxapram

Facteurs de risque 5

#1

Qui est à risque d'effets secondaires du doxapram ?

Les patients avec des antécédents cardiaques ou respiratoires sont à risque.
Antécédents médicaux Doxapram
#2

Le vieillissement augmente-t-il les risques liés au doxapram ?

Oui, les personnes âgées peuvent avoir un risque accru d'effets indésirables.
Vieillissement Doxapram
#3

Les femmes enceintes peuvent-elles utiliser le doxapram ?

Son utilisation chez les femmes enceintes doit être soigneusement évaluée par un médecin.
Femmes enceintes Doxapram
#4

Les patients asthmatiques sont-ils à risque ?

Oui, les patients asthmatiques doivent être surveillés lors de l'utilisation du doxapram.
Asthme Doxapram
#5

Quels médicaments augmentent les risques avec le doxapram ?

Les médicaments comme les inhibiteurs de la monoamine oxydase peuvent augmenter les risques.
Inhibiteurs de la monoamine oxydase Doxapram
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Doxapram : Questions médicales les plus fréquentes", "headline": "Doxapram : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Doxapram : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-05", "dateModified": "2026-05-26", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Doxapram" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Pyrrolidones", "url": "https://questionsmedicales.fr/mesh/D011760", "about": { "@type": "MedicalCondition", "name": "Pyrrolidones", "code": { "@type": "MedicalCode", "code": "D011760", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.773.812" } } }, "about": { "@type": "MedicalCondition", "name": "Doxapram", "alternateName": "Doxapram", "code": { "@type": "MedicalCode", "code": "D004315", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Sinno H P Simons", "url": "https://questionsmedicales.fr/author/Sinno%20H%20P%20Simons", "affiliation": { "@type": "Organization", "name": "Department of Pediatrics, Division of Neonatology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands." } }, { "@type": "Person", "name": "Irwin K M Reiss", "url": "https://questionsmedicales.fr/author/Irwin%20K%20M%20Reiss", "affiliation": { "@type": "Organization", "name": "Department of Pediatrics, Division of Neonatology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands." } }, { "@type": "Person", "name": "Robin L Cooper", "url": "https://questionsmedicales.fr/author/Robin%20L%20Cooper", "affiliation": { "@type": "Organization", "name": "Department of Biology, University of Kentucky, Lexington, KY 40506, USA." } }, { "@type": "Person", "name": "Robert B Flint", "url": "https://questionsmedicales.fr/author/Robert%20B%20Flint", "affiliation": { "@type": "Organization", "name": "Department of Pediatrics, Division of Neonatology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands. r.flint@erasmusmc.nl." } }, { "@type": "Person", "name": "Jarinda A Poppe", "url": "https://questionsmedicales.fr/author/Jarinda%20A%20Poppe", "affiliation": { "@type": "Organization", "name": "Department of Pediatrics, Division of Neonatology, Erasmus MC - Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands, j.poppe@erasmusmc.nl." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The effects of doxapram on time to tracheal extubation and early recovery in young morbidly obese patients scheduled for bariatric surgery: A randomised controlled trial.", "datePublished": "2020-Jun-00", "url": "https://questionsmedicales.fr/article/31842026", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/EJA.0000000000001144" } }, { "@type": "ScholarlyArticle", "name": "Doxapram for the prevention and treatment of apnea in preterm infants.", "datePublished": "2023-10-25", "url": "https://questionsmedicales.fr/article/37877431", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/14651858.CD014145.pub2" } }, { "@type": "ScholarlyArticle", "name": "Doxapram versus placebo in preterm newborns: a study protocol for an international double blinded multicentre randomized controlled trial (DOXA-trial).", "datePublished": "2023-10-10", "url": "https://questionsmedicales.fr/article/37817255", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13063-023-07683-5" } }, { "@type": "ScholarlyArticle", "name": "Oxygen saturation histogram classification system to evaluate response to doxapram treatment in preterm infants.", "datePublished": "2022-06-23", "url": "https://questionsmedicales.fr/article/35739260", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41390-022-02158-w" } }, { "@type": "ScholarlyArticle", "name": "Effect of doxapram on the electrical activity of the diaphragm waveform pattern of preterm infants.", "datePublished": "2022-03-23", "url": "https://questionsmedicales.fr/article/35274498", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ppul.25889" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétéromonocycliques", "item": "https://questionsmedicales.fr/mesh/D006573" }, { "@type": "ListItem", "position": 4, "name": "Pyrrolidines", "item": "https://questionsmedicales.fr/mesh/D011759" }, { "@type": "ListItem", "position": 5, "name": "Pyrrolidones", "item": "https://questionsmedicales.fr/mesh/D011760" }, { "@type": "ListItem", "position": 6, "name": "Doxapram", "item": "https://questionsmedicales.fr/mesh/D004315" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Doxapram - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Doxapram", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2026-05-26", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Doxapram", "description": "Comment le doxapram est-il utilisé dans le diagnostic ?\nQuels tests peuvent nécessiter du doxapram ?\nLe doxapram est-il utilisé en urgence ?\nQuels signes cliniques indiquent l'utilisation du doxapram ?\nLe doxapram est-il utilisé pour le diagnostic de l'apnée ?", "url": "https://questionsmedicales.fr/mesh/D004315#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Doxapram", "description": "Quels symptômes le doxapram traite-t-il ?\nLe doxapram peut-il provoquer des effets secondaires ?\nQuels symptômes indiquent une surdose de doxapram ?\nLe doxapram soulage-t-il la dyspnée ?\nQuels signes d'alerte nécessitent une attention médicale ?", "url": "https://questionsmedicales.fr/mesh/D004315#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Doxapram", "description": "Comment prévenir les complications respiratoires ?\nLe doxapram peut-il prévenir l'apnée du sommeil ?\nQuelles mesures préventives sont recommandées ?\nLe doxapram est-il préventif ou curatif ?\nComment gérer les risques respiratoires ?", "url": "https://questionsmedicales.fr/mesh/D004315#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Doxapram", "description": "Comment le doxapram est-il administré ?\nLe doxapram est-il utilisé en soins intensifs ?\nCombien de temps dure l'effet du doxapram ?\nLe doxapram peut-il être utilisé chez les enfants ?\nQuelles sont les alternatives au doxapram ?", "url": "https://questionsmedicales.fr/mesh/D004315#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Doxapram", "description": "Quelles complications peuvent survenir avec le doxapram ?\nLe doxapram peut-il causer des problèmes cardiaques ?\nComment gérer les effets indésirables du doxapram ?\nLe doxapram peut-il interagir avec d'autres médicaments ?\nQuels signes indiquent une complication grave ?", "url": "https://questionsmedicales.fr/mesh/D004315#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Doxapram", "description": "Qui est à risque d'effets secondaires du doxapram ?\nLe vieillissement augmente-t-il les risques liés au doxapram ?\nLes femmes enceintes peuvent-elles utiliser le doxapram ?\nLes patients asthmatiques sont-ils à risque ?\nQuels médicaments augmentent les risques avec le doxapram ?", "url": "https://questionsmedicales.fr/mesh/D004315#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment le doxapram est-il utilisé dans le diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Il est utilisé pour évaluer la fonction respiratoire en stimulant la respiration." } }, { "@type": "Question", "name": "Quels tests peuvent nécessiter du doxapram ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de fonction pulmonaire peuvent nécessiter l'administration de doxapram." } }, { "@type": "Question", "name": "Le doxapram est-il utilisé en urgence ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut être administré en cas d'insuffisance respiratoire aiguë." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent l'utilisation du doxapram ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Une hypoventilation ou une dépression respiratoire peuvent justifier son utilisation." } }, { "@type": "Question", "name": "Le doxapram est-il utilisé pour le diagnostic de l'apnée ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Il peut être utilisé pour évaluer la réponse respiratoire en cas d'apnée." } }, { "@type": "Question", "name": "Quels symptômes le doxapram traite-t-il ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Il traite les symptômes d'insuffisance respiratoire et de dépression respiratoire." } }, { "@type": "Question", "name": "Le doxapram peut-il provoquer des effets secondaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme l'hypertension ou des palpitations peuvent survenir." } }, { "@type": "Question", "name": "Quels symptômes indiquent une surdose de doxapram ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme l'anxiété, des tremblements ou des convulsions peuvent apparaître." } }, { "@type": "Question", "name": "Le doxapram soulage-t-il la dyspnée ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut soulager la dyspnée en stimulant la respiration." } }, { "@type": "Question", "name": "Quels signes d'alerte nécessitent une attention médicale ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des douleurs thoraciques ou des difficultés respiratoires doivent alerter." } }, { "@type": "Question", "name": "Comment prévenir les complications respiratoires ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut la vaccination et la gestion des maladies respiratoires chroniques." } }, { "@type": "Question", "name": "Le doxapram peut-il prévenir l'apnée du sommeil ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Non, il ne prévient pas l'apnée du sommeil, mais peut aider en cas de crise." } }, { "@type": "Question", "name": "Quelles mesures préventives sont recommandées ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le tabagisme et maintenir un poids santé sont des mesures préventives." } }, { "@type": "Question", "name": "Le doxapram est-il préventif ou curatif ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Le doxapram est principalement un traitement curatif, pas préventif." } }, { "@type": "Question", "name": "Comment gérer les risques respiratoires ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des risques inclut le suivi médical régulier et l'éducation des patients." } }, { "@type": "Question", "name": "Comment le doxapram est-il administré ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il est généralement administré par voie intraveineuse ou intramusculaire." } }, { "@type": "Question", "name": "Le doxapram est-il utilisé en soins intensifs ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est souvent utilisé en soins intensifs pour les patients en détresse respiratoire." } }, { "@type": "Question", "name": "Combien de temps dure l'effet du doxapram ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'effet du doxapram dure généralement de 30 minutes à 2 heures." } }, { "@type": "Question", "name": "Le doxapram peut-il être utilisé chez les enfants ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut être utilisé chez les enfants sous surveillance médicale." } }, { "@type": "Question", "name": "Quelles sont les alternatives au doxapram ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme la théophylline ou les bronchodilatateurs peuvent être utilisés." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le doxapram ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme l'hypertension ou des arythmies cardiaques peuvent survenir." } }, { "@type": "Question", "name": "Le doxapram peut-il causer des problèmes cardiaques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut provoquer des arythmies, surtout en cas de surdosage." } }, { "@type": "Question", "name": "Comment gérer les effets indésirables du doxapram ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La gestion inclut l'arrêt du médicament et le traitement des symptômes associés." } }, { "@type": "Question", "name": "Le doxapram peut-il interagir avec d'autres médicaments ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut interagir avec des médicaments comme les antidépresseurs ou les anesthésiques." } }, { "@type": "Question", "name": "Quels signes indiquent une complication grave ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des douleurs thoraciques ou des troubles de la conscience doivent alerter." } }, { "@type": "Question", "name": "Qui est à risque d'effets secondaires du doxapram ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les patients avec des antécédents cardiaques ou respiratoires sont à risque." } }, { "@type": "Question", "name": "Le vieillissement augmente-t-il les risques liés au doxapram ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent avoir un risque accru d'effets indésirables." } }, { "@type": "Question", "name": "Les femmes enceintes peuvent-elles utiliser le doxapram ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Son utilisation chez les femmes enceintes doit être soigneusement évaluée par un médecin." } }, { "@type": "Question", "name": "Les patients asthmatiques sont-ils à risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients asthmatiques doivent être surveillés lors de l'utilisation du doxapram." } }, { "@type": "Question", "name": "Quels médicaments augmentent les risques avec le doxapram ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Les médicaments comme les inhibiteurs de la monoamine oxydase peuvent augmenter les risques." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 26/05/2026

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Robin L Cooper

6 publications dans cette catégorie

Affiliations :
  • Department of Biology, University of Kentucky, Lexington, KY 40506, USA.

Robert B Flint

4 publications dans cette catégorie

Affiliations :
  • Department of Pediatrics, Division of Neonatology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands. r.flint@erasmusmc.nl.
  • Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands. r.flint@erasmusmc.nl.
  • Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. r.flint@erasmusmc.nl.

Jarinda A Poppe

4 publications dans cette catégorie

Affiliations :
  • Department of Pediatrics, Division of Neonatology, Erasmus MC - Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands, j.poppe@erasmusmc.nl.

Catherijne A J Knibbe

3 publications dans cette catégorie

Affiliations :
  • Leiden Amsterdam Center for Drug Research (LACDR), Division of Pharmacology, LACDR, Leiden University, Leiden, The Netherlands.
  • Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands.

Swantje Völler

3 publications dans cette catégorie

Affiliations :
  • Leiden Amsterdam Center for Drug Research (LACDR), Division of Pharmacology, LACDR, Leiden University, Leiden, The Netherlands.

Rachael M Vacassenno

3 publications dans cette catégorie

Affiliations :
  • Department of Biology, University of Kentucky, Lexington, KY, 40506-0225, USA.
Publications dans "Doxapram" :

Willem van Weteringen

3 publications dans cette catégorie

Affiliations :
  • Department of Pediatrics, Division of Neonatology, Erasmus MC - Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Pediatric Surgery, Erasmus MC - Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Anton H van Kaam

2 publications dans cette catégorie

Affiliations :
  • Department of Neonatology, Emma Children's Hospital, Academic Medical Centre Amsterdam, Amsterdam, The Netherlands.
  • Department of Neonatology, VU University Medical Center, Amsterdam, The Netherlands.

Aline G J Engbers

2 publications dans cette catégorie

Affiliations :
  • Leiden Amsterdam Center for Drug Research (LACDR), Division of Pharmacology, LACDR, Leiden University, Leiden, The Netherlands.

Birgit C P Koch

2 publications dans cette catégorie

Affiliations :
  • Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands.

Kaitlyn E Brock

2 publications dans cette catégorie

Affiliations :
  • Department of Biology, University of Kentucky, Lexington, KY, 40506-0225, USA.
Publications dans "Doxapram" :

Christian F Poets

2 publications dans cette catégorie

Affiliations :
  • Department of Neonatology, Tübingen University Hospital, Tübingen, Germany.

Wes Onland

2 publications dans cette catégorie

Affiliations :
  • Department of Neonatal Medicine, Amsterdam UMC, location University of Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam Reproduction and Development Research Institute, Amsterdam, The Netherlands.

Christine N Haddad

2 publications dans cette catégorie

Affiliations :
  • Department of Biology, University of Kentucky, Lexington, KY 40506-0225, USA. Electronic address: christine.haddad@uky.edu.
Publications dans "Doxapram" :

Sten P Willemsen

2 publications dans cette catégorie

Affiliations :
  • Department of Pediatrics, Division of Neonatology, Erasmus MC - Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Biostatistics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Manuel Kraft

2 publications dans cette catégorie

Affiliations :
  • Department of Cardiology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
  • DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg University Hospital, 69120 Heidelberg, Germany.
  • HCR, Heidelberg Centre for Heart Rhythm Disorders, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Kathrin I Foerster

2 publications dans cette catégorie

Affiliations :
  • Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Felix Wiedmann

2 publications dans cette catégorie

Affiliations :
  • Department of Cardiology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
  • DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg University Hospital, 69120 Heidelberg, Germany.
  • HCR, Heidelberg Centre for Heart Rhythm Disorders, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Sources (20 au total)

The effects of doxapram on time to tracheal extubation and early recovery in young morbidly obese patients scheduled for bariatric surgery: A randomised controlled trial.

Bariatric surgery is a well established treatment of the obese. Postoperative respiratory failure and airway obstruction after bariatric surgery can often be attributed to the residual depressant effe... The evaluation of the effects of doxapram on the outcomes of general anaesthesia following bariatric surgical procedures in the morbidly obese.... A single-blind randomised controlled trial with two parallel arms.... A tertiary care teaching hospital, Tehran, Iran, from 2017 to 2018.... In total, 100 patients (69 women) with at least class two obesity were included in two groups of equal sizes and underwent bariatric surgery.... The primary outcome was the time from the administration of doxapram to tracheal extubation. Secondary outcomes included vital signs and variables including peak expiratory flow rate, time to return t... Both groups underwent general anaesthesia. The intervention group received a single dose of doxapram 1 mg kg ideal body weight, immediately after reversal of neuromuscular blockade and after discontin... Doxapram decreased time to extubation, time to eye-opening and hand-squeezing, shortened recovery time and lowered end-tidal CO2 significantly (all P < 0.001). Moreover, it increased peak expiratory f... The postoperative use of doxapram improves peak expiratory flow rate, and decreases respiratory complications of anaesthesia during recovery in the morbidly obese undergoing bariatric surgery. Doxapra... Iranian Registry of Clinical Trials (IRCT) http://www.irct.ir/ number IRCT2017060712203N9....

Doxapram for the prevention and treatment of apnea in preterm infants.

Apnea of prematurity is a common problem in preterm infants that may have significant consequences on their development. Methylxanthines (aminophylline, theophylline, and caffeine) are effective in th... To evaluate the benefits and harms of doxapram administration on the incidence of apnea and other short-term and longer-term clinical outcomes in preterm infants.... We used standard, extensive Cochrane search methods. The latest search date was March 2023.... We included randomized controlled trials (RCTs) assessing the role of doxapram in prevention and treatment of apnea of prematurity and prevention of reintubation in preterm infants (less than 37 weeks... We used standard Cochrane methods. Our primary outcomes were clinical apnea, need for positive pressure ventilation after initiation of treatment, failed apnea reduction after two to seven days, and f... We included eight RCTs enrolling 248 infants. Seven studies (214 participants) provided data for meta-analysis. Five studied doxapram for treatment of apnea in preterm infants. Three studied doxapram ... In treating apnea of prematurity, doxapram may slightly reduce failure in apnea reduction when compared to no treatment and there may be little to no difference in side effects against both no treatme...

Doxapram versus placebo in preterm newborns: a study protocol for an international double blinded multicentre randomized controlled trial (DOXA-trial).

Apnoea of prematurity (AOP) is one of the most common diagnoses among preterm infants. AOP often leads to hypoxemia and bradycardia which are associated with an increased risk of death or disability. ... The DOXA-trial is a double blinded, multicentre, randomized, placebo-controlled trial conducted in the Netherlands, Belgium and Canada. A total of 396 preterm infants with a gestational age below 29 w... Doxapram has the potential to improve neonatal outcomes by improving respiration, but the safety concerns need to be weighed against the potential risks of invasive mechanical ventilation. It is unkno... ClinicalTrials.gov NCT04430790 and EUDRACT 2019-003666-41. Prospectively registered on respectively June and January 2020....

Oxygen saturation histogram classification system to evaluate response to doxapram treatment in preterm infants.

An oxygen saturation (SpO... This retrospective study included 61 very-low-birth-weight infants who received doxapram. SpO... The median (IQR) histogram type decreased from 4 (3-4) before to 3 (2-3) after therapy start (p < 0.001). The median (IQR) FiO... Classification of SpO... The SpO...

Effect of doxapram on the electrical activity of the diaphragm waveform pattern of preterm infants.

This study aimed to evaluate the change in the waveform pattern of the electrical activity of the diaphragm (Edi) following the administration of doxapram in extremely preterm infants ventilated with ... We conducted this retrospective cohort study in our neonatal intensive care unit between November 2019 and September 2021. The study participants were extremely preterm infants under the gestational a... Ten extremely preterm infants were included. Almost all the patients' respiratory condition improved after doxapram administration. The ventilatory parameters-Edi peak, Edi minimum, peak inspiratory p... Our results indicated that the proportion of Edi waveform patterns changed following doxapram administration. Edi waveform pattern analysis could be a sensitive indicator of effect with other interven...

The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age.

Apnea of prematurity can persist despite caffeine therapy in preterm infants. Doxapram may additionally support breathing. Although multiple small studies have reported the efficacy of doxapram, the s... In preterm neonates receiving caffeine, we determined caffeine plasma concentrations before, during, and directly after doxapram co-treatment and used these to develop a population PK model in NONMEM ... 166 plasma samples were collected from 39 preterm neonates receiving caffeine (median gestational age 25.6 [range 24.0-28.0] weeks) of which 65 samples were taken during co-treatment with doxapram (39... Caffeine clearance is not affected by concomitant doxapram therapy but shows a rapid maturation with postnatal age. As current guidelines do not adjust the caffeine dose with postnatal age, decreased ...

The bioavailability and maturing clearance of doxapram in preterm infants.

Doxapram is used for the treatment of apnea of prematurity in dosing regimens only based on bodyweight, as pharmacokinetic data are limited. This study describes the pharmacokinetics of doxapram and k... Data (302 samples) from 75 neonates were included with a median (range) gestational age (GA) 25.9 (23.9-29.4) weeks, bodyweight 0.95 (0.48-1.61) kg, and postnatal age (PNA) 17 (1-52) days at the start... A two-compartment model best described the pharmacokinetics of doxapram and keto-doxapram. PNA and GA affected the formation clearance of keto-doxapram (CL... Dosing of doxapram only based on bodyweight results in the highest exposure in preterm infants with the lowest PNA and GA. Therefore, dosing may need to be adjusted for GA and PNA to minimize the risk... Current dosing regimens of doxapram in preterm infants only based on bodyweight result in the highest exposure in infants with the lowest PNA and GA. Dosing of doxapram may need to be adjusted for GA ...

Doxapram for apnoea of prematurity and neurodevelopmental outcomes at age 5-6 years.

To assess the long-term neurodevelopmental impact of doxapram for treating apnoea of prematurity.... Secondary analysis of the French national cohort study EPIPAGE-2. Recruitment took place in 2011. A standardised neurodevelopmental assessment was performed at age 5-6 years. A 2:1 propensity score ma... Population-based cohort study.... All children born before 32 weeks' gestation alive at age 5-6 years.... Blind and standardised assessment by trained neuropsychologists and paediatricians at age 5-6 years.... Neurodevelopmental outcomes at age 5-6 years assessed by trained paediatricians and neuropsychologists: cerebral palsy, developmental coordination disorders, IQ and behavioural difficulties. A composi... The population consisted of 2950 children; 275 (8.6%) received doxapram. Median (IQR) gestational age was 29.4 (27.6-30.9) weeks. At age 5-6 years, complete neurodevelopmental assessment was available... In children born before 32 weeks' gestation, doxapram treatment for apnoea of prematurity was not associated with neurodevelopmental disabilities....

Pharmacologic interventions for the therapy of postanesthetic shivering in adults: a systematic review and network meta-analysis.

Shivering is a common side effect after general anesthesia. Risk factors are hypothermia, young age and postoperative pain. Severe complications of shivering are rare but can occur due to increased ox... Systematic review and frequentist network meta-analysis using the R package netmeta. Endpoints were the risk ratio (RR) of persistent shivering at one, five and 10 minutes after treatment with saline/... Thirty-two trials were eligible for data synthesis, including 28 pharmacological interventions. The largest network included 1431 patients. The network geometry was two-centered with most comparisons ... Nefopam, tramadol, pethidine and clonidine are the most effective treatments to stop postanesthetic shivering. The efficacy of doxapram is uncertain since different doses showed contradictory effects ...